Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
VolitionRX (VNRX)
:VNRX
Holding VNRX?
Track your performance easily
Earnings Data
Report Date
Mar 12, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.06Last Year’s EPS
-0.1Same Quarter Last Year
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2018
|% Change Since: -12.50%
|Next Earnings Date:Aug 13, 2018
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook with strong growth in sales and revenue, successful market expansion, and significant cost reductions. However, there are concerns about revenue predictability due to distributor stocking patterns, and the feline cancer test milestone remains pending.Company Guidance
In the third quarter of 2024, VolitionRx Limited reported significant progress, highlighted by the sale of over 110,000 Nu.Q Vet cancer tests, nearly double the 58,000 sold in all of 2023. The company's revenue growth accelerated, with a 100% increase year-to-date and a 37% rise in the quarter compared to the same periods in 2023. Year-to-date revenue totaled approximately $730,000. The Nu.Q Vet cancer test expanded its availability to 17 countries, with notable contributions from distributors like Fuji Film Vet Systems, Vetlab Poland, and Antech. Importantly, VolitionRx made substantial advancements in their human clinical initiatives, including lung cancer studies and sepsis research, which involved over 14,000 samples from 3,000 patients. Financially, the company achieved a 96% revenue growth for the first nine months of 2024 and a 36% year-over-year reduction in cash used in operating activities, aligning with their goal to be cash-neutral by 2025.Significant Increase in Nu.Q Vet Cancer Test Sales
Over 110,000 Nu.Q Vet cancer tests were sold in the first three quarters of 2024, compared to 58,000 in the entire year of 2023, marking a significant increase in sales volume.
Strong Revenue Growth
Revenue growth accelerated quarter-on-quarter with a year-to-date increase of 100% and a 37% increase in this quarter compared to the same periods in 2023.
Positive Financial Performance
The company recorded $1 million in revenue for the nine months ending September 30, 2024, reflecting a growth of 96% over the same period in 2023. Operating expenses were reduced by 28% compared to the same quarter last year.
Strategic Partnerships and Market Expansion
Partnerships with Fuji Film Vet Systems, Vetlab Poland, and Antech have led to successful launches and market penetration in multiple countries, including Japan and Poland.
---
VNRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VNRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $0.72 | $0.68 | -5.56% |
| Aug 14, 2024 | $0.55 | $0.57 | +3.64% |
| May 13, 2024 | $0.88 | $0.75 | -14.77% |
| Mar 25, 2024 | $0.72 | $0.75 | +4.17% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does VolitionRX (VNRX) report earnings?
VolitionRX (VNRX) is schdueled to report earning on Mar 12, 2025, TBA Not Confirmed.
What is VolitionRX (VNRX) earnings time?
VolitionRX (VNRX) earnings time is at Mar 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VNRX EPS forecast?
VNRX EPS forecast for the fiscal quarter 2024 (Q4) is -0.06.
---